Astellas Pharma Korea, Inc. clinical trials

A country office of Astellas Pharma Inc

The registry lists 19 studies whose lead sponsor is Astellas Pharma Korea, Inc.. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.

Studies

Recruiting first, then most recently updated. Showing 19 of 19. All Astellas Pharma Inc studies →

• A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.RecruitingNCT06902545

  Sponsor listed in the registry: Astellas Pharma Korea, Inc.

• A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV InjectionRecruitingNCT06011954

  Sponsor listed in the registry: Astellas Pharma Korea, Inc.

• A Study to Track the Safety of Vesomni in Men in South Korea Treated in Routine Clinical Practice for the Urinary Symptoms of Benign Prostatic Hyperplasia (Enlarged Prostate)Not yet recruitingNCT07619105

  Sponsor listed in the registry: Astellas Pharma Korea, Inc.

• A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) MutationCompletedNCT04691648

  Sponsor listed in the registry: Astellas Pharma Korea, Inc.

• Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer PatientsCompletedNCT06452212

  Sponsor listed in the registry: Astellas Pharma Korea, Inc.

• A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and SitagliptinCompletedNCT02452632Phase 3

  Sponsor listed in the registry: Astellas Pharma Korea, Inc.

• A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With AlbuminuriaTerminatedNCT03118713Phase 4

  Sponsor listed in the registry: Astellas Pharma Korea, Inc.

• Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)CompletedNCT01747577Phase 4

  Sponsor listed in the registry: Astellas Pharma Korea, Inc.

• A Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated With a 50% Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant RecipientsCompletedNCT02034747Phase 4

  Sponsor listed in the registry: Astellas Pharma Korea, Inc.

• A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic SyndromeCompletedNCT01763580Phase 4

  Sponsor listed in the registry: Astellas Pharma Korea, Inc.

• A Study to Evaluate the Effect of Advagraf Conversion From Prograf in Liver Transplant SubjectsCompletedNCT01882322Phase 4

  Sponsor listed in the registry: Astellas Pharma Korea, Inc.

• A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)CompletedNCT03737708Phase 4

  Sponsor listed in the registry: Astellas Pharma Korea, Inc.

• A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis PatientsTerminatedNCT01316133Phase 4

  Sponsor listed in the registry: Astellas Pharma Korea, Inc.

• Quality of Life Questionnaire Validation for Patients With Changed Tacrolimus Dosing After Kidney TransplantationCompletedNCT03623217

  Sponsor listed in the registry: Astellas Pharma Korea, Inc.

• A Study to Assess the Safety and Efficacy of a Tacrolimus Based Immunosuppressive Regimen in Stable Kidney Transplant Recipients Converted From Cyclosporine Based Immunosuppressive RegimenTerminatedNCT02963103Phase 4

  Sponsor listed in the registry: Astellas Pharma Korea, Inc.

• Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling DonorCompletedNCT02660684Phase 4

  Sponsor listed in the registry: Astellas Pharma Korea, Inc.

• Study to Evaluate the Safety and Efficacy of Advagraf vs Prograf in Kidney Transplantation Patients 1 Month After the TransplantationCompletedNCT01742624Phase 4

  Sponsor listed in the registry: Astellas Pharma Korea, Inc.

• A Single Center, Open-label, Randomized, Pilot Study to Evaluate the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF®, Versus Tacrolimus Twice Daily, PROGRAF® in Stable Renal RecipientsCompletedNCT01742676Phase 4

  Sponsor listed in the registry: Astellas Pharma Korea, Inc.

• A Study to Assess the Safety and Efficacy of ADVAGRAF (Tacrolimus Modified Release Formulation) in Kidney Transplant Patients Who Were Treated With PROGRAFCompletedNCT01839929Phase 4

  Sponsor listed in the registry: Astellas Pharma Korea, Inc.